Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients

Sichuan University

Status: Unknown

Conditions: Kidney Transplantation; Vaccine; SARS-CoV-2 Acute Respiratory Disease

Study type: Observational

Funder types: Other

Identifiers

NCT04969614

WestChina-COVID

Details and patient eligibility

About

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. However, immunocompromised individuals have been excluded from studies of SARS-CoV-2 vaccines. In such patients, the immune response to vaccination may be blunted. To better understand the immunogenicity of SARS-CoV-2 vaccines in transplant recipients, we quantified the humoral response to SARS-CoV-2 vaccine in kidney transplant recipients.

Enrollment: 300 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Receiving kidney transplantation in West China Hospital, Sichuan University

Exclusion criteria

1. History of rejection or infection over the previous 3 months; 2) receiving kidney transplantation >3 months; 3) Combined with HBV/HVC/HIV infection in the donor or recipient; 4) Malignancy history in the donor and recipient; 5) organ transplant history in the recipient.

Trial design

300 participants in 1 patient group

kidney transplant recipients

Description:

kidney transplant recipients receiving inactivated SARS-CoV-2 vaccine